Unlocking the potential of epigenetic therapeutics to revolutionize medicine
DURECT harnesses epigenetic modulation to treat serious and life-threatening conditions, including acute organ injury and cancer. Our unique approach targeting dysregulated DNA methylation has the potential to change the course of disease and improve patients’ lives.
Epigenetic Modulation
Many types of acute organ injuries and cancers are associated with dysregulation of the epigenome, such as DNA methylation. There is vast potential for epigenetic therapies to address the underlying pathophysiology by mitigating epigenomic dysregulation and helping to improve cellular function or suppress tumor growth.1-3
Alcohol-Associated Hepatitis (AH)
Clinical Trials
We are currently conducting a Phase 2b study (AHFIRM) in subjects with severe alcohol-associated hepatitis (AH) in more than 60 clinical trial sites across the U.S., EU, U.K., and Australia.


Partner with us
We welcome strategic partnerships to advance our collective goal to meaningfully impact patients’ lives and offer better therapeutic options.
Careers
Join our highly experienced, talented, and collaborative team as we strive to improve the course of human medicine with novel epigenetic therapies.


Press Releases
DURECT Corporation Reports Third Quarter 2023 Financial Results and Business Update
13 Nov, 2023, 16:05 ET – Webcast of Earnings Call Today, November 13th at 4:30 p.m. ET – Topline data from AHFIRM trial showed compelling
DURECT Corporation to Announce Third Quarter 2023 Financial Results and Provide a Business Update
09 Nov, 2023, 16:30 ET CUPERTINO, Calif., Nov. 9, 2023 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic
References
- Argemi J, Latasa MU, Atkinson SR, et al. Defective HNF4alpha-dependent gene expression as a driver of hepatocellular failure in alcoholic hepatitis. Nat Commun. 2019;10(1):3126. doi:10.1038/s41467-019-11004-3
- Mazzone R, Zwergel C, Artico M, et al. The emerging role of epigenetics in human autoimmune disorders. Clin Epigenetics. 2019;11(1):34. doi:10.1186/s13148-019-0632-2
- Herman A, Occean JR, Sen P. Epigenetic dysregulation in cardiovascular aging and disease. J Cardiovasc Aging. 2021;1:10. doi:10.20517/jca.2021.16
- Hassanein T, McClain CJ, Vatsalya V, et al. Safety, Pharmacokinetics, and Efficacy Signals of Larsucosterol (DUR-928) in Alcohol-Associated Hepatitis. Am J Gastroenterol. 2023;10.14309/ajg.0000000000002275.
- Data on File
- Hughes E, Hopkins LJ, Parker R. Correction: Survival from alcoholic hepatitis has not improved over time. PLoS One. 2018;13:e0195857.